Cargando…
Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes
Insulin-like growth factor 2 (IGF2) and the transformation related protein 53 (Trp53) are potent regulators of cell growth and metabolism in development and cancer. In vitro evidence suggests several mechanistic pathway interactions. Here, we tested whether loss of function of p53 leads to IGF2 liga...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494071/ https://www.ncbi.nlm.nih.gov/pubmed/22674894 http://dx.doi.org/10.1002/emmm.201101105 |
_version_ | 1782249356502499328 |
---|---|
author | Haley, Victoria L Barnes, David J Sandovici, Ionel Constancia, Miguel Graham, Christopher F Pezzella, Francesco Bühnemann, Claudia Carter, Emma J Hassan, A Bassim |
author_facet | Haley, Victoria L Barnes, David J Sandovici, Ionel Constancia, Miguel Graham, Christopher F Pezzella, Francesco Bühnemann, Claudia Carter, Emma J Hassan, A Bassim |
author_sort | Haley, Victoria L |
collection | PubMed |
description | Insulin-like growth factor 2 (IGF2) and the transformation related protein 53 (Trp53) are potent regulators of cell growth and metabolism in development and cancer. In vitro evidence suggests several mechanistic pathway interactions. Here, we tested whether loss of function of p53 leads to IGF2 ligand pathway dependency in vivo. Developmental lethality occurred in p53 homozygote null mice that lacked the paternal expressed allele of imprinted Igf2. Further lethality due to post-natal lung haemorrhage occurred in female progeny with Igf2 paternal null allele only if derived from double heterozygote null fathers, and was associated with a specific gene expression signature. Conditional deletion of Igf2(fl/fl) attenuated the rapid tumour onset promoted by homozygous deletion of p53(fl/fl). Accelerated carcinoma and sarcoma tumour formation in p53(+/−) females with bi-allelic Igf2 expression was associated with reductions in p53 loss of heterozygosity and apoptosis. Igf2 genetic dependency of the p53 null phenotype during development and tumour formation suggests that targeting the IGF2 pathway may be useful in the prevention and treatment of human tumours with a disrupted Trp53 pathway. |
format | Online Article Text |
id | pubmed-3494071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | WILEY-VCH Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-34940712012-11-09 Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes Haley, Victoria L Barnes, David J Sandovici, Ionel Constancia, Miguel Graham, Christopher F Pezzella, Francesco Bühnemann, Claudia Carter, Emma J Hassan, A Bassim EMBO Mol Med Research Articles Insulin-like growth factor 2 (IGF2) and the transformation related protein 53 (Trp53) are potent regulators of cell growth and metabolism in development and cancer. In vitro evidence suggests several mechanistic pathway interactions. Here, we tested whether loss of function of p53 leads to IGF2 ligand pathway dependency in vivo. Developmental lethality occurred in p53 homozygote null mice that lacked the paternal expressed allele of imprinted Igf2. Further lethality due to post-natal lung haemorrhage occurred in female progeny with Igf2 paternal null allele only if derived from double heterozygote null fathers, and was associated with a specific gene expression signature. Conditional deletion of Igf2(fl/fl) attenuated the rapid tumour onset promoted by homozygous deletion of p53(fl/fl). Accelerated carcinoma and sarcoma tumour formation in p53(+/−) females with bi-allelic Igf2 expression was associated with reductions in p53 loss of heterozygosity and apoptosis. Igf2 genetic dependency of the p53 null phenotype during development and tumour formation suggests that targeting the IGF2 pathway may be useful in the prevention and treatment of human tumours with a disrupted Trp53 pathway. WILEY-VCH Verlag 2012-08 2012-06-06 /pmc/articles/PMC3494071/ /pubmed/22674894 http://dx.doi.org/10.1002/emmm.201101105 Text en Copyright © 2012 EMBO Molecular Medicine |
spellingShingle | Research Articles Haley, Victoria L Barnes, David J Sandovici, Ionel Constancia, Miguel Graham, Christopher F Pezzella, Francesco Bühnemann, Claudia Carter, Emma J Hassan, A Bassim Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes |
title | Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes |
title_full | Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes |
title_fullStr | Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes |
title_full_unstemmed | Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes |
title_short | Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes |
title_sort | igf2 pathway dependency of the trp53 developmental and tumour phenotypes |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494071/ https://www.ncbi.nlm.nih.gov/pubmed/22674894 http://dx.doi.org/10.1002/emmm.201101105 |
work_keys_str_mv | AT haleyvictorial igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT barnesdavidj igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT sandoviciionel igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT constanciamiguel igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT grahamchristopherf igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT pezzellafrancesco igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT buhnemannclaudia igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT carteremmaj igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes AT hassanabassim igf2pathwaydependencyofthetrp53developmentalandtumourphenotypes |